1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Personalized Medicine for Cancer Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Immunotherapy
1.2.3 Targeted Therapy
1.2.4 Chemotherapy
1.2.5 Hormone Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Personalized Medicine for Cancer Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Breast Cancer
1.3.3 Blood Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Skin Cancer
1.3.7 Lung Cancer
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Personalized Medicine for Cancer Market Perspective (2017-2028)
2.2 Personalized Medicine for Cancer Growth Trends by Region
2.2.1 Personalized Medicine for Cancer Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Personalized Medicine for Cancer Historic Market Size by Region (2017-2022)
2.2.3 Personalized Medicine for Cancer Forecasted Market Size by Region (2023-2028)
2.3 Personalized Medicine for Cancer Market Dynamics
2.3.1 Personalized Medicine for Cancer Industry Trends
2.3.2 Personalized Medicine for Cancer Market Drivers
2.3.3 Personalized Medicine for Cancer Market Challenges
2.3.4 Personalized Medicine for Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Personalized Medicine for Cancer Players by Revenue
3.1.1 Global Top Personalized Medicine for Cancer Players by Revenue (2017-2022)
3.1.2 Global Personalized Medicine for Cancer Revenue Market Share by Players (2017-2022)
3.2 Global Personalized Medicine for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Personalized Medicine for Cancer Revenue
3.4 Global Personalized Medicine for Cancer Market Concentration Ratio
3.4.1 Global Personalized Medicine for Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalized Medicine for Cancer Revenue in 2021
3.5 Personalized Medicine for Cancer Key Players Head office and Area Served
3.6 Key Players Personalized Medicine for Cancer Product Solution and Service
3.7 Date of Enter into Personalized Medicine for Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Personalized Medicine for Cancer Breakdown Data by Type
4.1 Global Personalized Medicine for Cancer Historic Market Size by Type (2017-2022)
4.2 Global Personalized Medicine for Cancer Forecasted Market Size by Type (2023-2028)
5 Personalized Medicine for Cancer Breakdown Data by Application
5.1 Global Personalized Medicine for Cancer Historic Market Size by Application (2017-2022)
5.2 Global Personalized Medicine for Cancer Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Personalized Medicine for Cancer Market Size (2017-2028)
6.2 North America Personalized Medicine for Cancer Market Size by Country (2017-2022)
6.3 North America Personalized Medicine for Cancer Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Personalized Medicine for Cancer Market Size (2017-2028)
7.2 Europe Personalized Medicine for Cancer Market Size by Country (2017-2022)
7.3 Europe Personalized Medicine for Cancer Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Personalized Medicine for Cancer Market Size (2017-2028)
8.2 Asia-Pacific Personalized Medicine for Cancer Market Size by Country (2017-2022)
8.3 Asia-Pacific Personalized Medicine for Cancer Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Personalized Medicine for Cancer Market Size (2017-2028)
9.2 Latin America Personalized Medicine for Cancer Market Size by Country (2017-2022)
9.3 Latin America Personalized Medicine for Cancer Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Personalized Medicine for Cancer Market Size (2017-2028)
10.2 Middle East & Africa Personalized Medicine for Cancer Market Size by Country (2017-2022)
10.3 Middle East & Africa Personalized Medicine for Cancer Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Personalized Medicine for Cancer Introduction
11.1.4 Bayer Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.1.5 Bayer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Personalized Medicine for Cancer Introduction
11.2.4 GlaxoSmithKline Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.2.5 GlaxoSmithKline Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Personalized Medicine for Cancer Introduction
11.3.4 Novartis Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.3.5 Novartis Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Personalized Medicine for Cancer Introduction
11.4.4 Sanofi Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.4.5 Sanofi Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Personalized Medicine for Cancer Introduction
11.5.4 Pfizer Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.5.5 Pfizer Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Personalized Medicine for Cancer Introduction
11.6.4 Amgen Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.6.5 Amgen Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Personalized Medicine for Cancer Introduction
11.7.4 Merck Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.7.5 Merck Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Personalized Medicine for Cancer Introduction
11.8.4 Bristol-Myers Squibb Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Ariad Pharmaceuticals (Takeda)
11.9.1 Ariad Pharmaceuticals (Takeda) Company Detail
11.9.2 Ariad Pharmaceuticals (Takeda) Business Overview
11.9.3 Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Introduction
11.9.4 Ariad Pharmaceuticals (Takeda) Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.9.5 Ariad Pharmaceuticals (Takeda) Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Personalized Medicine for Cancer Introduction
11.10.4 Eli Lilly Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.10.5 Eli Lilly Recent Development
11.11 Roche
11.11.1 Roche Company Detail
11.11.2 Roche Business Overview
11.11.3 Roche Personalized Medicine for Cancer Introduction
11.11.4 Roche Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.11.5 Roche Recent Development
11.12 Boehringer Ingelheim
11.12.1 Boehringer Ingelheim Company Detail
11.12.2 Boehringer Ingelheim Business Overview
11.12.3 Boehringer Ingelheim Personalized Medicine for Cancer Introduction
11.12.4 Boehringer Ingelheim Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.12.5 Boehringer Ingelheim Recent Development
11.13 Johnson and Johnson
11.13.1 Johnson and Johnson Company Detail
11.13.2 Johnson and Johnson Business Overview
11.13.3 Johnson and Johnson Personalized Medicine for Cancer Introduction
11.13.4 Johnson and Johnson Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.13.5 Johnson and Johnson Recent Development
11.14 Teva Pharmaceuticals
11.14.1 Teva Pharmaceuticals Company Detail
11.14.2 Teva Pharmaceuticals Business Overview
11.14.3 Teva Pharmaceuticals Personalized Medicine for Cancer Introduction
11.14.4 Teva Pharmaceuticals Revenue in Personalized Medicine for Cancer Business (2017-2022)
11.14.5 Teva Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
